EUCTR2007-000607-15-ITActive, not recruitingNot Applicable
Phase II pilot multicenter study on efficacy and safety of liposomal amphotericin B (AmBisome) at 2 mg/kg/day in the treatment of candidemia and invasive candidiasis in nonneutropenic patients - CRITIC
GILEAD SCIENCES S.R.L.0 sitesStarted: October 12, 2007Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Active, not recruiting
- Sponsor
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Interventional
Eligibility Criteria
- Sex
- All
Inclusion Criteria
- •Patients admitted to ICU with - at least one positive culture isolation of Candida obtained within 96 hours prior to study entry from blood, IV catheters, abdominal drainage, soft tissue infection or any sample obtained by sterile procedure from normally sterile site, excluding urine, feces, sinuses, mucous membranes and BAL -and at least one of the following observed within 48 hours from the first positive culture: - temperature > 38C on 2 occasions at least 4 hours apart or one determination greater than 38.5C (internal, esophageal, timpani and bladder levels) - systolic blood pressure < 90 mmHg, or ³ 30 mmHg decrease in systolic BP from the subjects baseline (the period between obtaining the patient?s written, signed and dated informed consent, and the first study visit) - signs of inflammation from sterile sites ? bone, joint, skin, eye, esophagus, abdomen, excluding patients on artificial ventilation with positive BAL
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
Exclusion Criteria
- •Subjects who meet any of the following exclusion criteria are not to be enrolled in this study. Subjects with a history of allergy or intolerance to AmBisome Subjects who have received systemic antifungal therapy within 15 days prior to inclusion in the study Any severe cardiovascular disease (such as arrhythmias, in particular) which may constitute a contra-indication to AmBisome administration Subjects with an absolute neutrophil count of less than 500/mm3 in the 48 hours before enrolment in the study Subjects with a diagnosis of AIDS (positive HIV serology in association with either CD4 cell counts < 200 cells/mm3or history of an opportunistic infection /neoplasm), aplastic anemia, or Chronic Granulomatous Disease. Subjects with moderate or severe liver disease defined as any one or more of the following: Alkaline phosphatase, ALT, AST, or total bilirubin greater than 5 times the ULN (upper limit of normal) Subjects with a severe renal impairment defined by a serum creatinine of more than 2.5 mg/dL. Women who are pregnant or breastfeeding. Subjects who are unlikely to survive more than 24 hours. Subjects who previously participated in this study. Subjects who have received within the two weeks before study entry, are receiving or likely to receive any investigational drug (unlicensed new chemical entity).
Investigators
Similar Trials
Active, not recruiting
Not Applicable
A multicentre phase II study of the efficacy and safety of lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q) or monosomy 5. - Lenalidomide in high-risk myeloid disease with 5qEUCTR2007-000450-31-SEThe Nordic MDS group50
Active, not recruiting
Not Applicable
A multicentre phase II study of the efficacy and safety of lenalidomide in high-risk myeloid disease (high-risk MDS and AML) with a karyotype including del(5q) or monosomy 5. - Lenalidomide in high-risk myeloid disease with 5qHigh risk Myelodysplastic Syndrome (IPSS Int-2 or High) or Acute Myeloid Leukemia with a karyotype including del(5q) or monosomy 5MedDRA version: 9.1Level: LLTClassification code 10028533Term: Myelodysplastic syndromeMedDRA version: 9.1Level: LLTClassification code 10000886Term: Acute myeloid leukemiaEUCTR2007-000450-31-DKThe Nordic MDS group50
Active, not recruiting
Phase 1
A multicenter phase II study evaluating the effect and tolerability of vemurafenib in combination with Pegylated Interferon and Interleukin-2 in patients with metastatic melanoma positive for the BRAF-mutatioEUCTR2013-000773-71-DKDepartment of Oncology, Aarhus University Hospital50
Completed
Phase 2
Multicenter Phase II study to evaluate efficacy and safety of combination therapy with trastuzumab and pertuzumab in patients with HER2-positive metastatic colorectal cancercolorectal cancerJPRN-UMIN000027887ational Cancer Center Hospital East30
Active, not recruiting
Not Applicable
Study to assess the efficacy and the safetyof front-line therapy (Fludarabine, Cyclophosphamide and Ofatumumab) in young (=65 yrs) patientswith Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic LeukemiaEUCTR2011-005329-27-ITG.I.M.EM.A.Gruppo Italiano Malattie Ematologiche dell'Adulto